A phase i study of LY317615 (enzastaurin) and temozolomide in patients with gliomas (EORTC trial 26054)

Neuro-Oncology

Volumn 14, Issue 3, 2012, Pages 344-350

  Rampling, Roy ^a   Sanson, Marc ^b   Gorlia, Thiery ^c   Lacombe, Denis ^c   Lai, Christina ^a   Gharib, Myriam ^b   Taal, Walter ^d   Stoffregen, Clemens ^e   Decker, Rodney ^f   Van Den Bent, Martin J ^d  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c EORTC DATA CENTER   (Belgium)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e LILLY DEUTSCHLAND GMBH   (Germany)

^f ELI LILLY AND COMPANY   (United States)

Author keywords

Enzastaurin (Ly317615); phase 1; temozolomide; thrombocytopenia; toxicity

Indexed keywords

ENZASTAURIN; TEMOZOLOMIDE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLEEDING; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EXPOSURE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GLIOBLASTOMA; HEART DISEASE; HUMAN; HYPERTENSION; INTRACRANIAL PRESSURE; LOADING DRUG DOSE; LUNG EMBOLISM; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; RECOMMENDED DRUG DOSE; SIDE EFFECT; THROMBOCYTOPENIA; THROMBOEMBOLISM; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; DACARBAZINE; FEMALE; GLIOBLASTOMA; HUMANS; INDOLES; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; YOUNG ADULT;

EID: 84859544365     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nor221     Document Type: Article

References (19)

1. Stupp R, Mason WP, Van Den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987-996. (Pubitemid 40349501)
2. Yancopoulos G, Davis S, Gale N, Rudge J, Wiegand S, Holash J. Vascular-specific growth factors and blood vessel formation. Nature. 2000;407:242-248.
3. Ferrara N, Gerber H, LeCouter J. The Biology of VEGF and its receptors. Nat Med. 2003;9:669-676. (Pubitemid 36749215)
4. Zhou Y-H, Tan F, Hess KR, Yung WKA. The Expression of PAX6, PTEN, Vascular Endothelial Growth Factor, and Epidermal Growth Factor Receptor in Gliomas. Clin Cancer Res. 2003;9:3369-3375. (Pubitemid 37082732)
5. Kuo W-L, Liu J, Mauceri H, et al. Efficacy of the multi-kinase inhibitor enzastaurin is dependent on cellular signaling context. Molecular Cancer Therapeutics. 2010;9:2814-2824.
6. Carducci MA, Musib L, Kies MS, et al. Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer. J Clin Oncol. 2006;24:4092-4099. (Pubitemid 46622284)
7. Welch PA, Sinha VP, Cleverly AL, Darstein C, Flanagan SD, Musib LC. Safety, tolerability, QTc evaluation, and pharmacokinetics of single and multiple doses of enzastaurin HCl (LY317615), a protein kinase C-beta inhibitor, in healthy subjects. J Clin Pharmacol. 2007;47:1138-1151.
8. Keyes KA, Mann L, Sherman M, et al. LY317615 decreases plasma VEGF levels in human tumor xenograft-bearing mice. Cancer Chemother Pharmacol. 2004;53:133-140. (Pubitemid 38186992)
9. Graff JR, McNulty AM, Hanna KR, et al. The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res. 2005;65:7462-7469. (Pubitemid 41161281)
10. Fine HA, Kim L, Royce C, et al. Results from phase II trial of enzastaurin (LY317615) in patients with recurrent high grade gliomas. J Clin Oncol. 2005;15s (suppl; abstr 1504).
11. Fine HA, Kim L, Royce C, et al. A phase II trial of LY317615 in patients with recurrent high grade gliomas. J Clin Oncol. 2004;22:14s (suppl: abstr 1511).
12. Tabatabai G, Frank B, Wick A, et al. Synergistic antiglioma activity of radiotherapy and enzastaurin. Ann Neurol. 2007;61:153-161. (Pubitemid 46363842)
13. Macdonald DR, Cascino TL, Schold SC, Jr, Cairncross JG, et al. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8:1277-1280. (Pubitemid 20195640)
14. Kreisl TN, Kotliarova S, Butman JA, et al. A phase I/II trial of enzastaurin in patients with recurrent high-grade gliomas. Neuro-Oncology. 2010;12:181-189.
15. Wick W, Puduvalli VK, Chamberlain MC, et al. Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol. 2010;28:1168-1174.
16. Butowski N, Chang SM, Lamborn KR, et al. Enzastaurin plus temozolomide with radiation therapy in glioblastoma multiforme: a phase I study. Neuro-Oncol. 2010;12:608-613.
17. Nagane M, Nozue K, Shimizu S, et al. Prolonged and severe thrombocytopenia with pancytopenia induced by radiation-combined temozolomide therapy in a patient with newly diagnosed glioblastoma-Analysis of O6-methylguanine-DNA methyltransferase status. J Neuro Oncol. 2009;92:227-232.
18. Sure D, Dunn I, Norden A, Anderson WS. Intracerebral hemorrhage secondary to thrombocytopenia in a patient treated with temozolomide. Clin Neurol Neurosurg. 2010;112:741-742.
19. Galanis E, Buckner JC. Enzastaurin in the treatment of recurrent glioblastoma: a promise that did not materialize. J Clin Oncol. 2010;28:1097-1098.